中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 6
Jun.  2020
Turn off MathJax
Article Contents

Clinical significance of renaming nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2020.06.002
Research funding:

 

  • Published Date: 2020-06-20
  • The terms nonalcoholic steatohepatitis and nonalcoholic fatty liver disease( NAFLD) were first used in the 1980 s to describe a condition of similar liver histological changes to alcoholic liver disease,without excessive drinking nor other factors for liver injury. In-depth research on NAFLD has achieved rapid progress over the past 40 years; however,the unchanged nomenclature of the disease has become an obstacle for routine clinical practice and clinical trials. To overcome the shortcomings of the old term,the international consensus panel proposes to use the term metabolic associated fatty liver disease( MAFLD) to replace NAFLD and further puts forward the comprehensive and simple definition of MAFLD for clinical diagnosis,which makes MAFLD different from other liver diseases. Meanwhile,the panel suggests that MAFLD assessment and severity stratification should be extended beyond the simple dichotomous classification used at present.The new name MAFLD will become an important measure for optimizing clinical practice and improving clinical research and may bring benefits to physicians and patients.

     

  • loading
  • [1] DUFOUR JF. Time to abandon NASH?[J]. Hepatology,2016,63(1):9-10.
    [2] Redefining non-alcoholic fatty liver disease:What's in a name?[J]. Lancet Gastroenterol Hepatol,2020,5(5):419.
    [3] JIN Q,HUANG LJ,FAN JG. Debate on the name of non-alcoholic fatty liver disease[J]. J Southwest Med Univ,2020,43(2):93-96.(in Chinese)金倩,黄磊杰,范建高.非酒精性脂肪性肝病的更名之争[J].西南医科大学学报,2020,43(2):93-96.
    [4] SOFTIC S,KAHN CR. Fatty liver disease:Is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease?[J]. Eur J Gastroenterol Hepatol,2019,31(1):143.
    [5] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
    [6] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020.[Online ahead of print]
    [7] ESLAM M,NEWSOME PN,ANSTEE QM,et al. A new definition for metabolic associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020.[Online ahead of print]
    [8] ZENG J,FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol,2020,36(6):1205-1207.(in Chinese)曾静,范建高.非酒精性脂肪性肝病更名的临床意义[J].临床肝胆病杂志,2020,36(6):1205-1207.
    [9] FAN JG. Research advances in non-alcoholic fatty liver disease:A review of current status and prospect[J]. J Clin Hepatol,2015,31(7):999-1001.(in Chinese)范建高.非酒精性脂肪性肝病的研究现状与展望[J].临床肝胆病杂志,2015,31(7):999-1001.
    [10] FAN JG,KIM SU,WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol,2017,67(4):862-873.
    [11] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.
    [12] ZOU ZY,FAN JG. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease[J]. J Hepatol,2020.[Online ahead of print]
    [13] HUANG LJ,XU YH,FAN JG. Emphasis on clinical study of heterogeneity of non-alcoholic fatty liver disease[J]. Chin J Hepatol,2020,28(3):193-197.(in Chinese)黄磊杰,许炎煌,范建高.重视非酒精性脂肪性肝病异质性的临床研究[J].中华肝脏病杂志,2020,28(3):193-197.
    [14] ESLAM M,SANYAL AJ,GEORGE J. Toward more accurate nomenclature for fatty liver diseases[J]. Gastroenterology,2019,157(3):590-593.
    [15] ZHANG J,LIN S,JIANG D,et al. Chronic hepatitis B and non-alcoholic fatty liver disease:Conspirators or competitors?[J]. Liver Int,2020,40(3):496-508.
    [16] FAN JG. The name change of nonalcoholic steatohepatitis and its influence on clinical research[J]. Progr Pharm Sci,2020,44(3):161-163.(in Chinese)范建高.非酒精性脂肪性肝炎的更名及其对临床研究的影响[J].药学进展,2020,44(3):161-163.
    [17] SIDDIQUI MS,HARRISON SA,ABDELMALEK MF,et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science[J]. Hepatology,2018,67(5):2001-2012.
    [18] SU ST,ZHONG Y,MI YQ. Management of patients with non-alcoholic fatty liver disease[J]. J Prac Hepatol,2019,22(2):293-296.(in Chinese)苏淑婷,钟燕,宓余强.非酒精性脂肪性肝病分级分期管理研究进展[J].实用肝脏病杂志,2019,22(2):293-296.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1356) PDF downloads(388) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return